Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Pantec Biosolutions

This article was originally published in The Gray Sheet

  • News

Executive Summary

The laser-based drug delivery technology developer closes a $19 million investment round, led by StemCell Holding AG. Announced July 20, the funding will support ongoing clinical trials of Pantec's P.L.E.A.S.E. (Painless Laser Epidermal System) technology for delivering in vitro fertilization hormone therapy. "This financing will allow us to move ahead with the clinical development of the [IVF] platform and visualize our goal of reaching market approval in Europe," said CEO Christof Boehler. Headquartered in Liechtenstein, privately held Pantec's technology uses a handheld laser to create "controlled aqueous micropores in the epidermis" for transdermal delivery of high molecular weight drugs, the company explains. Pantec values the IVF hormone therapy market at $1.5 billion to $2 billion

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT029179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By